Involving Sex Selection Or Contraception Patents (Class 424/811)
-
Patent number: 8492516Abstract: Disclosed are methods, compositions, zona pellucida binding peptides and polypeptides, and expression vectors for use in species-specific immunocontraception of animals. The disclosed compositions may include immunogenic compositions or vaccines.Type: GrantFiled: March 9, 2012Date of Patent: July 23, 2013Assignee: Auburn UniversityInventors: Tatiana I. Samoylova, Henry J. Baker, Nancy Cox, Stephen Ditchkoff, Kent Van Kampen
-
Patent number: 8158366Abstract: Disclosed are methods of identifying peptides and compositions that bind to oocytes of animals in a species-specific manner. The methods utilize phage libraries and oocytes isolated from target species and non-target species.Type: GrantFiled: April 7, 2009Date of Patent: April 17, 2012Assignee: Auburn UniversityInventors: Tatiana I. Samoylova, Henry J. Baker, Nancy Cox, Stephen Ditchkoff
-
Patent number: 8080428Abstract: The present invention relates to diagnosis and/or treatment of medical conditions. The present invention relates to new method of diagnosing dry mucosa condition in a subject. The condition may be dry eye. The present invention also provides a method to monitor the efficacy of a treatment of a dry mucosa condition, a method of treating a dry mucosa condition and/or a diagnostic kit for a dry mucosa condition.Type: GrantFiled: April 26, 2007Date of Patent: December 20, 2011Assignees: Singapore Health Services Pte Ltd., Agency for Science, Technology and ResearchInventors: Roger Beuerman, Lei Zhou, Shouping Liu, He Yang, Donald Tan
-
Patent number: 8057992Abstract: Disclosed are methods, compositions, and zona pellucida binding peptides and polypeptides for use in immunocontraception of canines and other animals. The disclosed compositions may include pharmaceutical compositions. Methods for identifying peptides that bind to intact oocytes also are provided, in particular methods for identifying peptides that bind to zona pellucida of intact oocytes.Type: GrantFiled: November 7, 2008Date of Patent: November 15, 2011Assignee: Auburn UniversityInventors: Tatiana I. Samoylova, Henry J. Baker, Brenda Griffin, Kristina Pendergrass, Ludmila P. Globa, M. Daniel Givens, Kay P. Riddell, Nancy Cox
-
Patent number: 8012932Abstract: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.Type: GrantFiled: July 22, 2005Date of Patent: September 6, 2011Assignee: U.S. Environmental Protection AgencyInventor: Gary R. Klinefelter
-
Patent number: 7981626Abstract: A method for diagnosing endometriosis in a human subject comprising the steps of detecting a test amount of an antibody that specifically binds to SEQ ID NO:9 polypeptide or a truncated peptide comprising an epitope of SEQ ID NO: 9, in a sample from the subject; and comparing the test amount with a normal range of the antibody in a control sample from a subject who does not suffer from endometriosis, whereby a test amount above the normal range provides a positive indication in the diagnosis of endometriosis.Type: GrantFiled: July 22, 2009Date of Patent: July 19, 2011Assignee: Siemens Healthcare Diagnostics Inc.Inventors: A Said El Shami, Bruce Campbell, Dennis Sustarsic, Niver Sahakian
-
Patent number: 7754212Abstract: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.Type: GrantFiled: May 1, 2007Date of Patent: July 13, 2010Assignee: U.S. Environmental Protection AgencyInventor: Gary R. Klinefelter
-
Patent number: 7749987Abstract: A method of achieving contraception in a woman which comprises administering orally to said woman an estroprogestative composition comprising nomegestrol acetate and an estrogen is provided.Type: GrantFiled: January 3, 2007Date of Patent: July 6, 2010Assignee: Laboratorie TheramekInventors: Jacques Paris, Jean-Louis Thomas, Michel Lanquetin, Anny Lanquetin, legal representative, Jean-Philippe Lanquetin, legal representative
-
Patent number: 7604950Abstract: Disclosed are methods for determining the pregnancy status of a cow by detecting a pregnancy-associated glycoprotein (PAG) level that comprises proteins present in an acidic protein fraction of day 55 to day 60 bovine placental tissue. These methods may involve using novel polyclonal and monoclonal antibodies that have been generated using the acidic protein fraction as an immunogen. According to the method, the cow is pregnant when the PAG level is present at an elevated level in a sample obtained from the cow. The invention provides accurate methods of detecting pregnancy at early stages and has the benefit of allowing early post partum detection of pregnancy status with few false positive results. The antibodies for detecting the PAG level will also be useful in combination with detecting elevated progesterone levels, thus providing an even more effective pregnancy detection method.Type: GrantFiled: April 27, 2005Date of Patent: October 20, 2009Assignee: Monsanto Technology LLCInventors: Nagappan Mathialagan, Michael McGrath, Robert Schenkel
-
Patent number: 7531635Abstract: Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. MATER-protein specific binding agents, such as antibodies, are described. Methods are described for detecting MATER protein in a subject, including methods for determining whether a subject has a biological condition associated with abnormal Mater expression. Also provided are kits for detecting MATER protein in a subject.Type: GrantFiled: October 24, 2006Date of Patent: May 12, 2009Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Lawrence M. Nelson, Zhi-Bin Tong
-
Patent number: 7432067Abstract: Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater cDNA and protein sequences are provided. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for detecting an autoimmune response to MATER in a subject by detecting autoantibodies that recognize an epitope of a MATER protein. Also provided are methods for diagnosis of infertility or reduced fertility by detecting presence of MATER protein autoantibodies in a subject. The disclosure also describes kits for detecting MATER autoantibodies comprising MATER protein.Type: GrantFiled: October 24, 2006Date of Patent: October 7, 2008Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services & The National Institutes of HealthInventors: Lawrence M. Nelson, Zhi-Bin Tong
-
Patent number: 7211255Abstract: Oral, topical and injectable contraceptives, which are based on sperm protein 22 kDa (SP22) polypeptides and antibodies and infertility diagnostics are provided.Type: GrantFiled: July 22, 2004Date of Patent: May 1, 2007Assignee: United States of America The U.S. Environmental Protection AgencyInventor: Gary R. Klinefelter
-
Patent number: 7189812Abstract: Disclosed herein are novel nucleic acid and protein sequences that are essential to fertility. In particular, human Mater genomic, cDNA and protein sequences are provided, as are fragments and variants thereof. Functional MATER is required for female fertility; zygotes that arise from Mater null oocytes do not progress beyond the two-cell stage. Methods are described for using Mater molecules in diagnoses, prognosis, and treatment of infertility and reduced fertility, and kits related to such methods. Also provided are methods for using MATER as a contraceptive agent. The disclosure also describes compounds involved in such methods, and the identification of such compounds.Type: GrantFiled: October 1, 2003Date of Patent: March 13, 2007Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Lawrence M. Nelson, Zhi-Bin Tong
-
Patent number: 6596310Abstract: A method is provided for encapsulating sperm in a particle wherein the particle provides for the timed release of the sperm. In particular, the method uses a gel forming polymer to form the particle and a medium for maintaining most of the sperm in a non-capacitated stage while it is encapsulated. Further provided is a method for artificial insemination using the encapsulated sperm wherein the sperm is naturally or artificially capacitated after the artificial insemination. In an embodiment, capsules containing a core of sperm in a semen extender are formed as a mixture having membranes of different thicknesses to provide varying time of sperm release. In another embodiment, the sperm and extender are dispersed throughout solid beads that vary in chemical property and diameter to provide varying time of sperm release. The extender may be free of glucose, xanthine oxidase and H2O2, and contain fructose, fructose-6-phosphate, pyruvate, lactate or mixtures thereof as a carbohydrate source.Type: GrantFiled: August 23, 2000Date of Patent: July 22, 2003Assignees: Board of Trustees operating Michigan State University, University of MichiganInventors: Kuo-Chuan Karen Chou, Henry Y. Wang
-
Patent number: 6455041Abstract: Immunogenic epitopes of human zona pellucida protein useful in inducing antibodies to zona pellucida protein.Type: GrantFiled: November 17, 1999Date of Patent: September 24, 2002Inventor: Bonita S. Dunbar
-
Patent number: 6399579Abstract: Compositions for maintaining normal sexual function and treating sexual dysfunction in males and females comprising at least 15% by weight icariside I or at least 3.5% by weight anhydroicaritin, derived from extracts of plants belonging the Epimedium genus, and methods for preparing the same, are provided. The methods comprise subjecting an Epimedium extract to mild acid hydrolysis. Methods for maintaining normal sexual function and treating sexual dysfunction in both males and females are also provided, comprising oral administration of an effective amount of a novel composition of this invention comprising at least 15% by weight icariside I or at least 3.5% by weight anhydroicaritin.Type: GrantFiled: August 15, 2000Date of Patent: June 4, 2002Assignee: Hauser, Inc.Inventors: Rod Lenoble, Steven L. Richheimer, David Bailey, Coralee G. Mannila, Rebecca L. Nichols
-
Patent number: 6355235Abstract: Certain antibody molecules are so stable and so potent at immobilizing sperm as well as the pathogens for sexually transmitted diseases (STDs) that they make possible new prophylactic contraceptive methods: (a) for men, a skin lotion containing antibodies against sperm and against STD pathogens to be applied to the penis and external genitals during sexual activity, thereby delivering prophylactically effective doses of antibodies to virtually all areas of skin and epithelia across which most STDs, including AIDS, are usually transmitted, and, during vaginal intercourse, the penis will deliver a contraceptively reliable dose of the antibodies to the cervical region of the vagina; and (b) for women, intrauterine devices (IUDs) and intravaginal devices (IVDS) that release antibodies into the uterus or into the vagina to provide continuous protection against pregnancy and STDs for periods of months to years.Type: GrantFiled: November 23, 1999Date of Patent: March 12, 2002Assignee: Johns Hopkins UniversityInventors: Richard A. Cone, Kevin J. Whaley
-
Patent number: 6107102Abstract: A suspension of microfabricated microdevices for use in therapeutic applications is disclosed. The microdevices have a selected shape, and uniform dimensions preferably in the 100 nm to 10 Am range. Also disclosed are microfabrication methods for making such microdevices.Type: GrantFiled: August 7, 1997Date of Patent: August 22, 2000Assignee: Regents of the University of CaliforniaInventor: Mauro Ferrari
-
Patent number: 6045786Abstract: Certain antibody molecules are so stable and so potent at immobilizing sperm as well as the pathogens for sexually transmitted diseases (STDs) that they make possible new prophylactic contraceptive methods: (a) for men, a skin lotion containing antibodies against sperm and against STD pathogens to be applied to the penis and external genitals during sexual activity, thereby delivering prophylactically effective doses of antibodies to virtually all areas of skin and epithelia across which most STDs, including AIDS, are usually transmitted, and, during vaginal intercourse, the penis will deliver a contraceptively reliable dose of the antibodies to the cervical region of the vagina; and (b) for women, intrauterine devices (IUDs) and intravaginal devices (IVDs) that release antibodies into the uterus or into the vagina to provide continuous protection against pregnancy and STDs for periods of months to years.Type: GrantFiled: February 1, 1993Date of Patent: April 4, 2000Assignee: Johns Hopkins UniversityInventors: Richard A. Cone, Kevin J. Whaley
-
Patent number: 6027727Abstract: A method for specifically inducing transient infertility or permanent sterility in a host animal by selective vaccination with specific zona pellucida proteins or immunocontraceptively active fragments thereof. Novel zona pellucida DNA sequences encoding specific zona pellucida proteins are disclosed.Type: GrantFiled: November 9, 1993Date of Patent: February 22, 2000Assignee: Zonagen, Inc.Inventors: Jeffrey D. Harris, Kuang T. Hsu, Joseph S. Podolski
-
Patent number: 5843446Abstract: This invention relates to immunogenic luteinizing hormone releasing hormone (LHRH) peptides that lead to suppression of LHRH activity in males or females. These peptides are useful for inducing infertility and for treating prostatic hyperplasia, androgen-dependent carcinoma, prostatic carcinoma and testicular carcinoma in males. In females, the peptides are useful for treating endometriosis, benign uterine tumors, recurrent functional ovarian cysts and (severe) premenstrual syndrome as well as prevention or treatment of estrogen-dependent breast cancer. The subject peptides contain a helper T cell epitope and have LHRH at the C terminus. The helper T cell epitope aids in stimulating the immune response against LHRH. The peptides, optionally contain an invasin domain which acts as a general immune stimulator.Type: GrantFiled: June 7, 1995Date of Patent: December 1, 1998Assignee: United Biomedical, Inc.Inventors: Anna Efim Ladd, Chang Yi Wang, Timothy Joseph Zamb
-
Patent number: 5753231Abstract: A substantially purified intra-acrosomal primate sperm antigen useful in a contraceptive vaccine is disclosed herein. The antigen remains associated with primate sperm after the acrosome reaction. In particular, it remains associated with the inner and outer acrosomal membranes. Modified antigens and fragments thereof prepared by protein modification techniques are also disclosed as well as methods for purifying and using the antigens. Also disclosed are monoclonal and polyclonal antibodies to the antigen and methods of making and using such antibodies. Methods of use include purification of the antigen or use in various diagnostic techniques. Also disclosed are cDNA, expression vectors, and transformed microorganisms that produce the antigen.Type: GrantFiled: October 30, 1995Date of Patent: May 19, 1998Assignee: University of VirginiaInventors: John C. Herr, Richard M. Wright
-
Patent number: 5721348Abstract: The disclosure relates to isolated DNA encoding all or a portion of a surface protein present in sperm of a mammal. This surface protein of sperm is essential for fertilization in the mammal. Preferably, the sperm surface protein is the PH-20 protein.Type: GrantFiled: October 21, 1991Date of Patent: February 24, 1998Assignee: University of ConnecticutInventors: Paul Primakoff, Diana G. Myles
-
Patent number: 5439362Abstract: A method of sorting living cells based on DNA content. Mammalian sperm subpopulations enriched in X- or Y-sperm. X- and Y-enriched sperm-plasma-membrane vesicles. Substantially pure sex-associated membrane (SAM) proteins. Antibodies binding to X- or Y-SAM proteins, essentially free of antibodies binding to Y- or X-SAM proteins respectively, or to the H-Y antigen. Semen samples enriched for X- or Y-sperm. Methods for increasing the probability that offspring will be male or female comprising the step of allowing as sperm from an enriched semen sample to fertilize an ovum. Methods for increasing the probability that offspring will be male or female comprising the step of immunizing a female with X- or Y-SAM proteins. Methods of decreasing fertility comprising the step of immunizing a female with both X- and Y-sperm. Methods of increasing the probability that mammalian offspring will carry a gene for a particular sex-chromosome linked trait.Type: GrantFiled: July 25, 1994Date of Patent: August 8, 1995Assignee: Cytogam, Inc.Inventor: Glenn F. Spaulding
-
Patent number: 5436157Abstract: A substantially purified intra-acrosomal human sperm antigen useful in a contraceptive vaccine is disclosed herein. The antigen remains associated with human sperm after the acrosome reaction. In particular, it remains associated with the inner and outer acrosomal membranes. Modified antigens and fragments thereof prepared by protein modification techniques are also disclosed as well as methods for purifying and using the antigens. Also disclosed are monoclonal and polyclonal antibodies to the antigen and methods of making and using such antibodies. Methods of use include purification of the antigen or use in various diagnostic techniques. Also disclosed are cDNA, expression vectors, and transformed microorganisms that produce the antigen.Type: GrantFiled: February 16, 1990Date of Patent: July 25, 1995Assignee: The University of Virginia Alumni Patents FoundationInventors: John C. Herr, Richard M. Wright
-
Patent number: 5403586Abstract: This invention relates to the preparation of novel fusion proteins which comprise an analogue of LHRH and TraTp or an analogue of TraTp. The fusion proteins of the invention are useful as components of vaccines for the inhibition or control of reproductive functions in vertebrate hosts. The invention also relates to polynucleotide molecules encoding the fusion proteins, to transformant hosts expressing the fusion proteins and to methods of inhibiting or controlling reproductive function in vertebrate hosts using the fusion proteins or vaccines of the invention.Type: GrantFiled: June 25, 1991Date of Patent: April 4, 1995Assignee: Biotechnology Australia Ptl Ltd.Inventors: Gregory J. Russell-Jones, Andrew G. Stewart, Con G. Tsonis
-
Patent number: 5348866Abstract: This invention relates to a DNA sequence comprising at least part of a porcine zona pellucida PZP-4.alpha. or -4.beta. gene coding for an amino acid sequence represented by SEQ ID NO: 1 or SEQ ID NO: 2, respectively, in SEQUENCE LISTING.This invention also relates to an expression system and to expression of said DNA.In addition, this invention relates to an immunogenic recombinant polypeptide or peptide which comprises at least part of said amino acid sequence and which is obtained by expressing said DNA, and to a contraceptive vaccine for use in human or other animals which comprises said polypeptide or peptide as an active ingredient.Type: GrantFiled: March 20, 1992Date of Patent: September 20, 1994Assignees: Shinzo Isojima, Tonen CorporationInventors: Shinzo Isojima, Akiko Akatani, Yuichi Okazaki, Masanobu Sugimoto